{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-022103","form_type":"8-K","ticker":"MGRX","cik":"0001938046","company_name":"MANGOCEUTICALS, INC.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.106488+00:00","generated_at":"2026-05-16T20:37:34.913626+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mangoceuticals partners with Lilly and Novo Nordisk for GLP-1 access programs; $99/month membership","bullets":["Launches MangoRx Direct and PeachesRx Direct providing access to Zepbound (Eli Lilly) and Wegovy (Novo Nordisk) via telehealth.","Membership fee $99/month includes unlimited virtual visits, progress tracking, lifestyle coaching; GLP-1 meds from $499/month cash-pay.","No insurance required; prescriptions fulfilled via LillyDirect Self Pay, NovoCare Pharmacy, or local pharmacies.","Company highlights White House deal lowering government GLP-1 pricing to $245/month and $50 Medicare copays from mid-2026.","CEO Jacob Cohen states program targets 42% of U.S. adults with obesity, aiming to make treatment simple and sustainable."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-022103","json":"https://secwatch.observer/filing/0001493152-25-022103.json","markdown":"https://secwatch.observer/filing/0001493152-25-022103.md","text":"https://secwatch.observer/filing/0001493152-25-022103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225022103/0001493152-25-022103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938046/000149315225022103/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:37:34.913626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}